Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Moderate Buy” from Analysts

Biodesix, Inc. (NASDAQ:BDSX) has received an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $1.75.

BDSX has been the subject of several research reports. Scotiabank lowered their price objective on shares of Biodesix from $3.00 to $2.00 and set a “sector outperform” rating for the company in a research report on Wednesday, May 21st. Wall Street Zen raised shares of Biodesix to a “sell” rating in a research report on Saturday.

Biodesix Stock Down 9.2%

Shares of NASDAQ:BDSX opened at $0.38 on Friday. Biodesix has a 52 week low of $0.17 and a 52 week high of $1.85. The company has a debt-to-equity ratio of 41.11, a quick ratio of 2.14 and a current ratio of 2.14. The company has a market capitalization of $55.00 million, a PE ratio of -1.29 and a beta of 1.00. The company has a 50 day moving average price of $0.40 and a two-hundred day moving average price of $0.46.

Biodesix’s stock is set to reverse split on Monday, September 15th. The 1-20 reverse split was announced on Thursday, September 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, September 12th.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Biodesix had a negative return on equity of 269.67% and a negative net margin of 53.66%.The company had revenue of $20.02 million for the quarter, compared to the consensus estimate of $18.47 million. Biodesix has set its FY 2025 guidance at EPS. Analysts forecast that Biodesix will post -0.35 earnings per share for the current year.

Insider Activity

In related news, Director Jack W. Schuler acquired 3,488,372 shares of the stock in a transaction dated Friday, August 29th. The stock was bought at an average price of $0.43 per share, with a total value of $1,499,999.96. Following the completion of the transaction, the director directly owned 24,406,546 shares of the company’s stock, valued at approximately $10,494,814.78. The trade was a 16.68% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 5,906 shares of company stock worth $2,481 over the last ninety days. 30.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd grew its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares in the last quarter. Birchview Capital LP lifted its stake in Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock valued at $3,586,000 after acquiring an additional 154,937 shares during the last quarter. Monashee Investment Management LLC lifted its stake in Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock valued at $2,532,000 after acquiring an additional 549,121 shares during the last quarter. Blair William & Co. IL lifted its stake in Biodesix by 33.3% in the first quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock valued at $78,000 after acquiring an additional 31,000 shares during the last quarter. Finally, Shay Capital LLC acquired a new stake in Biodesix in the fourth quarter valued at $431,000. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.